Skip Navigation


JAC Advance Access originally published online on March 10, 2005
Journal of Antimicrobial Chemotherapy 2005 55(5):800-804; doi:10.1093/jac/dki063
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
55/5/800    most recent
dki063v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (25)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Montes, M. L.
Right arrow Articles by Arribas, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Montes, M. L.
Right arrow Articles by Arribas, J. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions{at}oupjournals.org

Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors

Maria Luisa Montes1, Federico Pulido2, Carlos Barros3, Emilia Condes3, Rafael Rubio2, Concepción Cepeda2, Fernando Dronda4, Antonio Antela4, José Sanz5, Enrique Navas4, Pilar Miralles6, Juan Berenguer6, Susana Pérez4, Angeles Zapata7, Juan J. González-García1, Jose Ma Peña1, J. J. Vázquez1 and Jose R. Arribas1,*

1 Internal Medicine Service and 7 Biochemistry Service, La Paz Hospital, Autónoma University School of Medicine; 2 HIV Unit, Hospital 12 de Octubre, Complutense University School of Medicine; 3 Hospital de Móstoles; 4 Servicio de Enfermedades Infecciosas, Hospital Ramón y Cajal, Alcalá University School of Medicine; 5 Internal Medicine Service, Hospital Príncipe de Asturias, Alcalá University School of Medicine; 6 Servicio de Enfermedades Infecciosas, Hospital Gregorio Marañón, Complutense University School of Medicine, Madrid, Spain

* Correspondence address. Hospital La Paz, Consulta de Medicina Interna II, Paseo de la Castellana, No. 261, 28046 Madrid, Spain. Tel: +34-91-727-7099; Fax: +34-91-729-00-33; Email: josearribas{at}telefonica.net

Objectives: The aim of this study was to evaluate the frequency, characteristics and risk factors of lipid changes associated with lopinavir/ritonavir treatment in antiretroviral-naive patients.

Methods: A prospective cohort of 107 antiretroviral-naive HIV-infected patients was followed for 12 months after starting lopinavir/ritonavir-based highly active antiretroviral therapy.

Results: At 12 months, percentages of patients with hypercholesterolaemia and hypertriglyceridaemia were 17.4% and 40%, respectively. Mean increases in total cholesterol and triglycerides were 40.7 and 73.3 mg/dL. There was a significant increase in both low-density and high-density (HDL) cholesterol, and no increase in the total cholesterol/HDL ratio (from 4.16 at baseline to 4.49 after 12 months). Baseline cholesterol > 200 mg/dL and triglycerides > 150 mg/dL were independent risk factors for dyslipidaemia, while hepatitis C coinfection appeared to be protective.

Conclusions: Patients with elevated lipid values at baseline have the greatest risk of developing hypercholesterolaemia and hypertriglyceridaemia after starting lopinavir/ritonavir. Antiretroviral-naive patients coinfected with hepatitis C have a low risk of developing hyperlipidaemia after starting lopinavir/ritonavir.

Keywords: antiretroviral therapy , hypercholesterolaemia , hypertriglyceridaemia , cholesterol , triglycerides , high-density cholesterol , low-density cholesterol


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Int Assoc Physicians AIDS Care (Chic Ill)Home page
J.-L. Meynard, K. Lacombe, J.-M. Poirier, O. Massot, B. Lefebvre, O. Bouchaud, J.-B. Guiard-Schmidt, A. Martinez, P. Benlian, and P.-M. Girard
Sustained Increase of HDL Cholesterol Over a 72-Week Period in HIV-Infected Patients Exposed to an Antiretroviral Regimen Including Lopinavir/Ritonavir
J Int Assoc Physicians AIDS Care (Chic Ill), December 1, 2008; 7(6): 311 - 316.
[Abstract] [PDF]

Home page
 J Antimicrob ChemotherHome page
A. Leon, E. Martinez, M. Sarasa, Y. Lopez, J. Mallolas, E. De Lazzari, M. Laguno, A. Milincovic, J. L. Blanco, M. Larrousse, et al.
Impact of steady-state lopinavir plasma levels on plasma lipids and body composition after 24 weeks of lopinavir/ritonavir-containing therapy free of thymidine analogues
J. Antimicrob. Chemother., October 1, 2007; 60(4): 824 - 830.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
S. S. Kaplan and C. B. Hicks
Safety and antiviral activity of lopinavir/ritonavir-based therapy in human immunodeficiency virus type 1 (HIV-1) infection
J. Antimicrob. Chemother., August 1, 2005; 56(2): 273 - 276.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.